ALPHAMAB ONCOLO.DL-000002 (3NK) — Cash Flow Quality Index
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Cash Flow Quality Index of 1.28x as of December 2024. Operating cash flow of €212.34 Million exceeds net income of €166.34 Million, indicating high earnings quality where cash backs reported profits. Explore 3NK operating cash flow to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
ALPHAMAB ONCOLO.DL-000002 Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for ALPHAMAB ONCOLO.DL-000002 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check ALPHAMAB ONCOLO.DL-000002 (3NK) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for ALPHAMAB ONCOLO.DL-000002 (2024–2024)
Year-by-year earnings quality comparison for ALPHAMAB ONCOLO.DL-000002. For live market cap and the full company financial profile, see 3NK stock market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.28x | €212.34 Million | €166.34 Million | — |